Truist Securities Maintains Buy on Insmed, Raises Price Target to $68
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Insmed (NASDAQ:INSM) and raised the price target from $48 to $68.
May 29, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained its Buy rating on Insmed and raised the price target from $48 to $68.
The raised price target from $48 to $68 by Truist Securities indicates increased confidence in Insmed's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100